

Thursday 16 May 2024

12:00 - 14:00	Registration and buffet lunch	
14:00 - 14:10	Introduction and welcome	<b>Jane Armitage</b> (CTSU, Oxford)
14:10 - 14:40	REPRIEVE - pitavastatin to prevent cardiovascular disease in patients with HIV	<b>Steven Grinspoon</b> (Harvard, Boston)
14:40 - 15:00	ASCEND PLUS update - oral semaglutide to reduce complications of diabetes	<b>Rohan Wijesurendra</b> (CTSU, Oxford)
15:00 - 15:20	ASCEND Eye - The effect of aspirin and omega-3 fatty acids on common eye diseases	<b>Emily Sammons</b> (CTSU, Oxford)
15:20 - 16:00	Tea and coffee	
16:00 - 16:30	Trials in cardiogenic shock and out-of-hospital cardiac arrest	<b>Christian Hassager</b> (Rigshospitalet, Copenhagen)
16:30 - 16:50	ORION-4 trial update - inclisiran to prevent cardiovascular disease	<b>Louise Bowman</b> (CTSU, Oxford)
16:50 - 17:20	Extending the age range for routine breast cancer screening: the AgeX Trial	<b>Toral Gathani</b> (Cancer Epidemiology Unit, Oxford)
19:00 - 20:00	Drinks reception	
20:00	Dinner	

Friday 17 May 2024

07:00 - 08:45	Registration and breakfast	
09:00 - 09:05	Introduction and welcome	<b>Rory Collins</b> (CTSU, Oxford)
09:05 - 09:30	Too frail for flozins?	<b>Kaitlin Mayne</b> (CTSU, Oxford)
09:30 - 09:40	Long-term follow up of the EMPA-KIDNEY trial	<b>Nikita Agrawal</b> (CTSU, Oxford)
09:40 - 10:00	EASi-KIDNEY update: aldosterone synthase inhibition for patients with chronic kidney disease	<b>Parminder Judge</b> (CTSU, Oxford)
10:00 - 10:30	Decentralised trials in the UK and beyond	<b>Isla Mackenzie</b> (MEMO Research, Dundee)
10:30 - 11:00	Tea and coffee	
11:00 - 11:30	Population-based studies for cardiovascular benefit in Denmark: DANCANVAS and beyond	<b>Axel Diederichsen</b> (Odense University Hospital, Denmark)
11:30 - 12:00	On the path to cure chronic kidney disease	<b>Christoph Wanner</b> (Nephrology, Wurzburg)
12:00 - 13:00	Lunch	